Evidence map›Paper›PMID 28101757›Full record

Trial reportInternational journal of clinical oncology2017

Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan.

Kazuhito Minami, Masaru Morita, Yasunori Emi, Masahiro Okamoto, Eiji Tanaka, Shigeyuki Nagata, Tetsuo Touyama, Kippei Ohgaki, Takaho Tanaka, Hiroshi Okumura and 9 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kazuhito MinamiDepartment of Gastroenterological Surgery, National Kyushu Cancer Center, Notame 3-1-1, Minami-ku, Fukuoka, 811-1395, Japan. minami.k@nk-cc.go.jp.
Masaru MoritaDepartment of Gastroenterological Surgery, National Kyushu Cancer Center, Notame 3-1-1, Minami-ku, Fukuoka, 811-1395, Japan.
Yasunori EmiDepartment of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Masahiro OkamotoDepartment of Surgery, Oita Red Cross Hospital, Oita, Japan.
Eiji TanakaDepartment of Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
Shigeyuki NagataDepartment of Surgery, Nakatsu Municipal Hospital, Oita, Japan.
Tetsuo TouyamaDepartment of Surgery, Nakagami Hospital, Okinawa, Japan.
Kippei OhgakiDepartment of Gastrointestinal Surgery, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan.
Takaho TanakaDepartment of Surgery, Social Insurance Tagawa Hospital, Fukuoka, Japan.
Hiroshi OkumuraDepartment of Surgery, Kagoshima Kouseiren Hospital, Kagoshima, Japan.
Toyokuni SuenagaDepartment of Surgery, Nanpuh Hospital, Kagoshima, Japan.
Shoji TokunagaMedical Information Center, Kyushu University Hospital, Fukuoka, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshihiro KakejiDivision of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan.
Yoshito AkagiDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Hideo BabaDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Shoji NatsugoeDepartment of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Yoshihiko MaeharaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kyushu Study Group of Clinical Cancer (KSCC)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of oral capecitabine as adjuvant chemotherapy for Japanese patients with resected colon cancer was unclear. We previously planned and conducted a prospective feasibility study (KSCC0803) and reported on the safety of oral capecitabine as adjuvant chemotherapy for Japanese patients with resected stage III colon cancer. The purpose of the current study was to assess the survival results from that study.

methodsThe study subjects were Japanese patients with resected stage III colon cancer. The protocol adjuvant regimen consisted of oral capecitabine 1250 mg/m

resultsNinety-seven patients were registered between September 2008 and August 2009 and treated with the protocol regimen. The median follow-up time was 60.7 months. The 3- and 5-year DFS rates were 71.2% [95% confidence interval (CI): 61.7-79.8%] and 69.7% (95% CI: 59.4-77.8%), respectively. The 3- and 5-year OS rates were 92.6% (95% CI: 85.2-96.4%) and 84.5% (95% CI: 75.1-90.5%), respectively.

conclusionsThe survival results in this study are in line with those of previously reported, reliable, studies. The safety and tolerability of the protocol regimen have already been confirmed. Oral capecitabine is acceptable as adjuvant chemotherapy for Japanese patients with resected stage III colon cancer.

Indexed as

Administration, OralAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemotherapy, AdjuvantColonic NeoplasmsDisease-Free SurvivalFeasibility StudiesFemaleHumansJapanMaleMiddle AgedProspective StudiesCapecitabineAdjuvant chemotherapyCapecitabineColon cancerFeasibility studyJapaneseX-ACT trial

Identifiers

PMID28101757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.